Orexo AB ADR ORXOY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ORXOY is a good fit for your portfolio.
News
-
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
-
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
-
Orexo publishes the Annual and Sustainability Report for 2023
-
Correction: Notice of Annual General Meeting of Orexo
-
Notice of Annual General Meeting of Orexo
-
Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
-
Orexo strengthens its sustainability work by establishing a social financing framework
-
Orexo and Sobi agree to advance feasibility study with AmorphOX
Trading Information
- Previous Close Price
- $1.44
- Day Range
- $1.40–1.40
- 52-Week Range
- $0.76–1.71
- Bid/Ask
- $1.40 / $1.68
- Market Cap
- $48.23 Mil
- Volume/Avg
- 655 / 403
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.80
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo’s groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo’s headquarters in Uppsala, Sweden.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 116
- Website
- https://www.orexo.com
Valuation
|
Metric
|
ORXOY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.18 |
Price/Sales | 0.80 |
Price/Cash Flow | — |
Price/Earnings
ORXOY
Financial Strength
|
Metric
|
ORXOY
|
|---|---|
Quick Ratio | 1.52 |
Current Ratio | 1.74 |
Interest Coverage | −2.59 |
Quick Ratio
ORXOY
Profitability
|
Metric
|
ORXOY
|
|---|---|
Return on Assets (Normalized) | −13.69% |
Return on Equity (Normalized) | −106.26% |
Return on Invested Capital (Normalized) | −15.38% |
Return on Assets
ORXOY
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Kcdsxglpt | Nxhxv | $69.8 Bil | |
ZTS
| Zoetis Inc Class A | Gpclfgllx | Gpqym | $68.9 Bil | |
HLN
| Haleon PLC ADR | Tdcnycv | Kqxy | $37.7 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Gflfmbdy | Nzvcg | $14.8 Bil | |
VTRS
| Viatris Inc | Hxzmvydvw | Fjck | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Ydnrwknnr | Srjn | $11.9 Bil | |
CTLT
| Catalent Inc | Xgtbwbmk | Sgdzwv | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Lxxbzkm | Mndy | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Fvvcvgcvv | Cqf | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Xjwnjzdz | Cghxnm | $3.5 Bil |